Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (231-240 of 315) with videos related to

Pageof 32
Sort By:
Nucleic Acids Research|January 10, 2023
canSAR: update to the cancer translational research and drug discovery knowledgebasePatrizio di Micco, Albert A Antolin, Costas Mitsopoulos, et al.
Cancer Research|October 12, 2010
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signatureNathalie Gaspar, Lynley Marshall, Lara Perryman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Molecular Cancer Therapeutics|June 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory NeuroblastomaEvon Poon, Tong Liang, Qiong Gao, et al.
Cancer Research|August 4, 2006
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomographyJulius Leyton, John P Alao, Marco Da Costa, et al.
Molecular Cancer Therapeutics|December 20, 2007
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activityFlorence Chan, Chongbo Sun, Meg Perumal, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.
Chemistry & Biology|June 26, 2004
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoformsLisa Wright, Xavier Barril, Brian Dymock, et al.
Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.
Molecular & Cellular Proteomics : MCP|December 22, 2022
Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global ChangesRahul S Samant, Silvia Batista, Mark Larance, et al.
Pageof 32

Showing results (231-240 of 315) with videos related to

Sort By:
Pageof 32
Nucleic Acids Research|January 10, 2023
canSAR: update to the cancer translational research and drug discovery knowledgebasePatrizio di Micco, Albert A Antolin, Costas Mitsopoulos, et al.
Cancer Research|October 12, 2010
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signatureNathalie Gaspar, Lynley Marshall, Lara Perryman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumorsJohann S de Bono, Rebecca Kristeleit, Anthony Tolcher, et al.
Molecular Cancer Therapeutics|June 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory NeuroblastomaEvon Poon, Tong Liang, Qiong Gao, et al.
Cancer Research|August 4, 2006
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomographyJulius Leyton, John P Alao, Marco Da Costa, et al.
Molecular Cancer Therapeutics|December 20, 2007
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activityFlorence Chan, Chongbo Sun, Meg Perumal, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.
Chemistry & Biology|June 26, 2004
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoformsLisa Wright, Xavier Barril, Brian Dymock, et al.
Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.
Molecular & Cellular Proteomics : MCP|December 22, 2022
Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global ChangesRahul S Samant, Silvia Batista, Mark Larance, et al.
Pageof 32